BiotechTube
Home/Genelux/James L. Tyree
JL

James L. Tyree

Lead Independent Director

Genelux

Therapeutic Areas

OncologyImmuno-Oncology

Genelux Pipeline

DrugIndicationPhase
Olvi-VecPlatinum-Resistant/Refractory Ovarian CancerPhase 3
V2ACT ImmunotherapyUndisclosed Solid TumorsPhase 1
V-VET1Canine CancersVeterinary

Leadership Team at Genelux

TZ
Thomas Zindrick
President, Chief Executive Officer and Chairman
View full Genelux profile